title: Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients.
abstract: BACKGROUND
  Positron emission tomography (PET) imaging of brain amyloid (Aβ) and neurofibrillary tangle (NFT) load is a candidate biomarker of Alzheimer's disease (AD).
  
  
  OBJECTIVE
  To compare brain Aβ and NFT load and glucose metabolism in advanced elderly (70 years and older) patients with AD and healthy controls (HCs) by PET with [18F]FDDNP and [18F]FDG.
  
  
  METHODS
  Seven AD patients (mean ± SD age 79.3 ± 3.6 y, Mini-Mental State Examination (MMSE) score 22.1 ± 2.5) and eight HCs (mean age ± SD, 75.7 ± 3.9 y; MMSE score 29.0 ± 1.2) underwent PET with [18F]FDDNP and [18F]FDG.
  
  
  RESULTS
  Global [18F]FDDNP uptake was significantly higher (p < 0.05) in AD patients (1.15 ± 0.04) than in HCs (1.10 ± 0.06), while global brain metabolism was lower in AD patients than in HCs (AD patients 0.96 ± 0.09; HCs 1.13 ± 0.11; p < 0.05). In HCs, brain glucose metabolism was correlated with age for both the global [18F]FDG SUVr and in the parietal and posterior cingulate regions, while no correlation was found between age and [18F]FDDNP uptake. In AD patients, global [18F]FDDNP uptake and uptake in the frontal and anterior cingulate regions of interest were correlated with MMSE score, while no correlation was observed with brain glucose metabolism.
  
  
  CONCLUSIONS
  Imaging Aβ load and NFT with [18F]FDDNP can distinguish AD patients from HCs in an advanced elderly population. It seems to be less sensitive than [18F]FDG to the brain changes observed with normal aging, but more sensitive to cognitive decline in advanced elderly AD patients.
authors.affiliation: Université François Rabelais de Tours & INSERM U930, Tours, France.
authors.forename: Clovis
authors.initials: C
authors.lastname: Tauber
authors.forename: Emilie
authors.initials: E
authors.lastname: Beaufils
authors.forename: Caroline
authors.initials: C
authors.lastname: Hommet
authors.forename: Maria Joao
authors.initials: MJ
authors.lastname: Ribeiro
authors.forename: Johnny
authors.initials: J
authors.lastname: Vercouillie
authors.forename: Emilie
authors.initials: E
authors.lastname: Vierron
authors.forename: Karl
authors.initials: K
authors.lastname: Mondon
authors.forename: Jean Philippe
authors.initials: JP
authors.lastname: Cottier
authors.forename: Valérie
authors.initials: V
authors.lastname: Gissot
authors.forename: Denis
authors.initials: D
authors.lastname: Guilloteau
authors.forename: Vincent
authors.initials: V
authors.lastname: Camus
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D001921:Brain / Q000000981:diagnostic imaging* / Q000473:pathology; D001931:Brain Mapping; D004174:Diprenorphine / Q000031:analogs & derivatives*; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008609:Mental Status Schedule; D049268:Positron-Emission Tomography
chemical_list: C411951:6-O-(2-(18F)fluoroethyl)-6-O-desmethyldiprenorphine; D019788:Fluorodeoxyglucose F18; D004174:Diprenorphine; D005947:Glucose